HRP20050697A2 - Citostatički pripravak lijeka - Google Patents
Citostatički pripravak lijeka Download PDFInfo
- Publication number
- HRP20050697A2 HRP20050697A2 HR20050697A HRP20050697A HRP20050697A2 HR P20050697 A2 HRP20050697 A2 HR P20050697A2 HR 20050697 A HR20050697 A HR 20050697A HR P20050697 A HRP20050697 A HR P20050697A HR P20050697 A2 HRP20050697 A2 HR P20050697A2
- Authority
- HR
- Croatia
- Prior art keywords
- diamine
- molecular weight
- guanidine
- relative molecular
- amino groups
- Prior art date
Links
- 150000002357 guanidines Chemical class 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229920000642 polymer Polymers 0.000 title claims description 6
- 230000001085 cytostatic effect Effects 0.000 title abstract description 12
- 239000000824 cytostatic agent Substances 0.000 title abstract description 10
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000006068 polycondensation reaction Methods 0.000 claims abstract description 5
- 150000004985 diamines Chemical class 0.000 claims description 16
- -1 triethylene glycol diamine Chemical class 0.000 claims description 13
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 8
- 239000012907 medicinal substance Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 4
- 125000005702 oxyalkylene group Chemical group 0.000 claims description 4
- 229920001281 polyalkylene Polymers 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0017403A AT501983B1 (de) | 2003-02-04 | 2003-02-04 | Zytostatisches arzneimittel enthaltend ein polymeres guanidinderivat |
| PCT/AT2004/000023 WO2004069898A1 (de) | 2003-02-04 | 2004-01-22 | Polymere guanidinderivate als zytostatisches arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050697A2 true HRP20050697A2 (hr) | 2006-04-30 |
Family
ID=32831402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050697A HRP20050697A2 (hr) | 2003-02-04 | 2005-08-03 | Citostatički pripravak lijeka |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7820719B2 (he) |
| EP (2) | EP1597302B1 (he) |
| JP (1) | JP4970929B2 (he) |
| KR (1) | KR20050109478A (he) |
| CN (1) | CN100339415C (he) |
| AT (2) | AT501983B1 (he) |
| AU (1) | AU2004208854B2 (he) |
| BR (1) | BRPI0407266A (he) |
| CA (1) | CA2515331A1 (he) |
| CY (1) | CY1107192T1 (he) |
| DE (2) | DE502004007805D1 (he) |
| DK (1) | DK1597302T3 (he) |
| EA (1) | EA011127B1 (he) |
| ES (1) | ES2297371T3 (he) |
| HK (1) | HK1088915A1 (he) |
| HR (1) | HRP20050697A2 (he) |
| IL (1) | IL170025A (he) |
| MX (1) | MXPA05008267A (he) |
| PT (1) | PT1597302E (he) |
| SI (1) | SI1597302T1 (he) |
| WO (1) | WO2004069898A1 (he) |
| ZA (1) | ZA200505991B (he) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT501983B1 (de) * | 2003-02-04 | 2007-03-15 | Geopharma Produktionsgmbh | Zytostatisches arzneimittel enthaltend ein polymeres guanidinderivat |
| AT500998B1 (de) * | 2003-03-20 | 2008-10-15 | Geopharma Produktionsgmbh | Antimikrobiell wirkendes arzneimittel |
| US9233993B2 (en) | 2009-06-30 | 2016-01-12 | Monsanto Technology Llc | N-phosphonomethylglycine guanidine derivative salts |
| EP2338342A1 (de) | 2009-12-24 | 2011-06-29 | Sebastian Oberwalder | Polyharnstoff mit bioziden Eigenschaften |
| EP2338923B1 (de) | 2009-12-24 | 2017-10-18 | Sebastian Oberwalder | Polyurethan mit einem bioziden Polyharnstoff als Comonomer |
| CA2816171A1 (en) | 2010-10-29 | 2012-05-03 | Mindinvest Holdings Ltd. | Liposomal drug composition containing a polymeric guanidine derivative |
| US20140228528A1 (en) * | 2011-11-02 | 2014-08-14 | Mindinvest Holdings Ltd. | Polyguanidine silicate and use thereof |
| AT513858B1 (de) * | 2013-01-25 | 2014-08-15 | Sealife Pharma Gmbh | Neue bioaktive Polymere |
| WO2019245488A1 (en) * | 2018-06-21 | 2019-12-26 | Ucar Dilek | Guanidinium derivatives as immunity-inducing agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2336605A (en) * | 1941-12-29 | 1943-12-14 | Du Pont | Pesticide |
| JPS5587145A (en) * | 1978-12-22 | 1980-07-01 | Fuji Photo Film Co Ltd | Developing method for silver halide photographic material |
| JPS59183698A (ja) | 1983-04-02 | 1984-10-18 | Wako Pure Chem Ind Ltd | 基質又は酵素活性の定量方法 |
| NL191481C (nl) | 1983-04-05 | 1995-08-04 | Draegerwerk Ag | Inrichting voor anesthesie met terugademing. |
| US4891423A (en) * | 1989-03-20 | 1990-01-02 | Stockel Richard F | Polymeric biguanides |
| DE4002403A1 (de) * | 1990-01-27 | 1991-08-01 | Degussa | Verfahren zur herstellung von biozid wirksamen polymeren guanidinsalzen |
| DE4002404A1 (de) * | 1990-01-27 | 1991-08-01 | Degussa | Loesungen polymerer guanidinsalze mit erhoehter biozidwirksamkeit, verfahren zu ihrer herstellung und verwendung |
| RU1816769C (ru) | 1990-12-28 | 1993-05-23 | Московский научно-исследовательский и проектно-изыскательский институт "МосводоканалНИИпроект" | Привитые сополимеры полиоксиалкилена на полиалкиленгуанидине в качестве поверхностно-активных веществ и катионного полиэлектролита |
| JP3716052B2 (ja) * | 1996-06-25 | 2005-11-16 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料の処理方法および脱銀処理組成物 |
| KR100807406B1 (ko) * | 2000-05-11 | 2008-02-25 | 피.오.씨. 오일 인더스트리 테크놀로지 베라퉁스게스.엠.비.에이치. | 구아니딘 염에 기초한 살생 중합체 |
| AT501983B1 (de) * | 2003-02-04 | 2007-03-15 | Geopharma Produktionsgmbh | Zytostatisches arzneimittel enthaltend ein polymeres guanidinderivat |
-
2003
- 2003-02-04 AT AT0017403A patent/AT501983B1/de not_active IP Right Cessation
-
2004
- 2004-01-22 KR KR1020057014225A patent/KR20050109478A/ko not_active Application Discontinuation
- 2004-01-22 PT PT04704150T patent/PT1597302E/pt unknown
- 2004-01-22 DE DE502004007805T patent/DE502004007805D1/de not_active Expired - Lifetime
- 2004-01-22 BR BR0407266-9A patent/BRPI0407266A/pt not_active IP Right Cessation
- 2004-01-22 WO PCT/AT2004/000023 patent/WO2004069898A1/de active IP Right Grant
- 2004-01-22 EP EP04704150A patent/EP1597302B1/de not_active Expired - Lifetime
- 2004-01-22 AT AT06020911T patent/ATE403690T1/de not_active IP Right Cessation
- 2004-01-22 SI SI200430596T patent/SI1597302T1/sl unknown
- 2004-01-22 EP EP06020911A patent/EP1734064B1/de not_active Expired - Lifetime
- 2004-01-22 EA EA200501245A patent/EA011127B1/ru not_active IP Right Cessation
- 2004-01-22 CN CNB2004800035490A patent/CN100339415C/zh not_active Expired - Fee Related
- 2004-01-22 AU AU2004208854A patent/AU2004208854B2/en not_active Ceased
- 2004-01-22 JP JP2006501334A patent/JP4970929B2/ja not_active Expired - Fee Related
- 2004-01-22 ES ES04704150T patent/ES2297371T3/es not_active Expired - Lifetime
- 2004-01-22 CA CA002515331A patent/CA2515331A1/en not_active Abandoned
- 2004-01-22 ZA ZA200505991A patent/ZA200505991B/xx unknown
- 2004-01-22 DK DK04704150T patent/DK1597302T3/da active
- 2004-01-22 MX MXPA05008267A patent/MXPA05008267A/es active IP Right Grant
- 2004-01-22 DE DE502004005602T patent/DE502004005602D1/de not_active Expired - Lifetime
-
2005
- 2005-08-01 IL IL170025A patent/IL170025A/he not_active IP Right Cessation
- 2005-08-03 US US11/197,465 patent/US7820719B2/en not_active Expired - Fee Related
- 2005-08-03 HR HR20050697A patent/HRP20050697A2/hr not_active Application Discontinuation
-
2006
- 2006-08-22 HK HK06109319A patent/HK1088915A1/xx not_active IP Right Cessation
-
2008
- 2008-02-13 CY CY20081100168T patent/CY1107192T1/el unknown
-
2010
- 2010-09-27 US US12/891,181 patent/US8198333B2/en not_active Expired - Fee Related
-
2012
- 2012-06-12 US US13/494,812 patent/US20130040388A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050697A2 (hr) | Citostatički pripravak lijeka | |
| Hoet et al. | Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions | |
| Firsching et al. | Antiproliferative and angiostatic activity of suramin analogues | |
| Romanelli et al. | In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems | |
| Rodrigues et al. | Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution | |
| DE60023660T2 (de) | Antizymmodulatoren sowie deren verwendung | |
| CN104788689B (zh) | 一种可还原降解聚两性离子纳米胶束及其制备方法 | |
| CN111632153A (zh) | 一种化学基因药物共载的靶向纳米递药系统及其制备方法 | |
| US11583509B2 (en) | Compound for treating cancer and diabetes | |
| CN101511351A (zh) | 治疗癌症的组合方法 | |
| KR102013041B1 (ko) | 항암제가 담지된 나노구조체를 유효성분으로 포함하는 간암 치료용 약학조성물 | |
| Kovář et al. | The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl) methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line | |
| Št'Astný et al. | HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia | |
| Lampidis et al. | Nuclear and mitochondrial effects of adriamycin in singly isolated pulsating myocardial cells | |
| CN116139293A (zh) | 一种靶向调控肿瘤血管新生的两亲性分子及靶向肿瘤组织的酸响应型多肽纳米药物 | |
| Askar et al. | Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity | |
| Miyagi et al. | Crystal violet combined with Merocyanine 540 for the ex vivo purging of hematopoietic stem cell grafts | |
| CN112386600B (zh) | 湖贝甲素在制备预防急性肾损伤药物中的用途 | |
| Su et al. | Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against Fn-associated colorectal tumor | |
| WO2022101512A1 (en) | Therapeutic-oligonucleotides activated by nucleases | |
| CN117338777A (zh) | 靶向IKKε激酶抑制剂及其在抗肿瘤药物中的应用 | |
| WO2009009365A1 (en) | Compositions and methods for preventing or treating disease caused by polyomavirus infection or reactivation in a mammalian subject |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: GEOPHARMA PRODUKTIONSGMBH, AT |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20110725 Year of fee payment: 8 |
|
| OBST | Application withdrawn |